Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Fineline Cube Jul 8, 2026
Company Drug

Eli Lilly Mounjaro Fails to Win EU Approval for HFpEF Heart Failure Indication

Fineline Cube Feb 3, 2026

Eli Lilly (NYSE: LLY) announced that the European Medicines Agency (EMA) drug advisory panel declined to...

Company Drug

Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation

Fineline Cube Feb 3, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has...

Company Drug

Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China

Fineline Cube Feb 3, 2026

Chiesi Group’s China unit announced that the National Medical Products Administration (NMPA) has granted marketing...

Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Fineline Cube Feb 3, 2026

SanegeneBio, a Suzhou‑based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a...

Company Deals

Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership

Fineline Cube Feb 3, 2026

Zonsen Peplib Biotech Inc., a China‑based polypeptide lead compound developer, announced a collaboration with Eli...

Company Drug

Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis

Fineline Cube Feb 3, 2026

Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for...

Company Deals

WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases

Fineline Cube Feb 3, 2026

WuXi Biologics (HKG: 2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T‑cell engager...

Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026

The National Medical Products Administration (NMPA) released the 101st batch of reference drugs for generic...

Company Deals

Zenshine Pharma Files for Hong Kong IPO with $357M Valuation

Fineline Cube Feb 2, 2026

Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main...

Company Deals

Moderna Partners with Recordati on mRNA-3927 for Rare Propionic Acidemia

Fineline Cube Feb 2, 2026

Moderna Inc. (NASDAQ: MRNA) announced a global partnership with Italy‑based Recordati for mRNA-3927, an investigational mRNA...

Company Deals

Illumina Completes $350M SomaLogic Acquisition to Expand Proteomics Portfolio

Fineline Cube Feb 2, 2026

Illumina (NASDAQ: ILMN) announced the completion of its acquisition of SomaLogic, a leader in data‑driven proteomics...

Company Medical Device

Microport EP Medtech’s EasyEcho ICE Catheter Wins NMPA Market Clearance

Fineline Cube Feb 2, 2026

Shanghai Microport EP Medtech Co., Ltd. (SHA: 688351) announced that the National Medical Products Administration...

Policy / Regulatory

NHSA Targets NRDL Fund Supervision in 2026 Crackdown

Fineline Cube Feb 2, 2026

China’s National Healthcare Security Administration (NHSA) this week issued the “Notice on Further Enhancing the...

Company

Regeneron Q4 Revenue Grows 3% to $3.9B on EYLEA HD and Dupixent Strength

Fineline Cube Feb 2, 2026

Regeneron Pharmaceuticals (NASDAQ: REGN) reported fourth‑quarter 2025 revenues of $3.884 billion , up 3% year‑on‑year (YOY), bringing...

Company Deals

Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis

Fineline Cube Feb 2, 2026

Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd....

Company Drug

Sciwind’s Ecnoglutide Wins NMPA Nod as First cAMP‑Biased GLP‑1 Agonist

Fineline Cube Feb 2, 2026

Sciwind Biosciences Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved ecnoglutide...

Policy / Regulatory

FDA Opens PreCheck Applications to Strengthen Domestic Drug Manufacturing

Fineline Cube Feb 2, 2026

The U.S. Food and Drug Administration this week began accepting applications for the FDA PreCheck...

Company Drug

Ab&b Bio-Tech’s Trivalent Influenza Vaccine Wins NMPA Nod for All Ages

Fineline Cube Feb 2, 2026

Ab&b Bio-Tech Co.,Ltd. (HKG: 2627) announced that the National Medical Products Administration (NMPA) has granted...

Company Drug

Sanofi Rezurock Wins EU Backing for Graft‑Versus‑Host Disease

Fineline Cube Feb 2, 2026

Sanofi (NASDAQ: SNY) announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human...

Company Drug

CMS-D017 Gets NMPA Nod for PNH Clinical Trial

Fineline Cube Feb 2, 2026

China Medical System Holdings (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has...

Posts pagination

1 … 74 75 76 … 692

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
  • AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
  • OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model
  • Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus
  • Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Others

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

Others

OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model

Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.